Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC [0.03%]
EGFR突变型非小细胞肺癌患者从第一代或第二代表皮生长因子受体酪氨酸激酶抑制剂转换至奥希替尼治疗
Fumio Imamura,Takako Inoue,Kei Kunimasa et al.
Fumio Imamura et al.
Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. Materials & methods: Clinical...
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer [0.03%]
体重指数与晚期非小细胞肺癌免疫检查点抑制剂疗效相关性的研究现状分析
Alain Gelibter,Mario Occhipinti,Simona Pisegna et al.
Alain Gelibter et al.
Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer [0.03%]
基于术后液态活检的早期肺癌分子残留病灶检测的优化研究
Anna L McGuire,Curtis B Hughesman,Melissa K McConechy et al.
Anna L McGuire et al.
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib [0.03%]
关于ALK阳性晚期非小细胞肺癌脑转移患者管理的成本分析：阿来替尼对比克唑替尼
Dolores Isla,Bartomeu Massuti,Martín Lázaro et al.
Dolores Isla et al.
Aim: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. ...
Katherine Gordon
Katherine Gordon
Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis [0.03%]
T1-3N0期非小细胞肺癌脑转移的风险分析：基于人群的研究
Michael T Milano,James E Bates,Justin Budnik et al.
Michael T Milano et al.
Aim: Several consensus guidelines recommend against routine brain imaging at diagnosis of T1-3N0 non-small cell lung cancer (NSCLC). Methods: ...
Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation [0.03%]
三期非小细胞肺癌患者序贯免疫治疗的实践挑战
Nikhil A Shukla,Nasser H Hanna
Nikhil A Shukla
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? [0.03%]
化疗和/或免疫检查点抑制剂在晚期非小细胞肺癌一线治疗中的地位和最佳策略选择？
Luigi Della Gravara,Ciro Battiloro,Rosa Cantile et al.
Luigi Della Gravara et al.
Can tumor mutational burden determine the most effective treatment for lung cancer patients? [0.03%]
肿瘤突变负荷能确定肺癌患者的最有效治疗方案吗？
Shixiang Wang,Zaoke He,Xuan Wang et al.
Shixiang Wang et al.
Keywords: TMB; biomarker; cancer immunotherapy; immune checkpoint inhibitor; lung cancer; tumor mutational burden.
Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer [0.03%]
凸面支气管内超声：一币两面。非小细胞肺癌活检与分期的挑战
Konstantinos Sapalidis,Konstantinos Romanidis,Panagoula Oikonomou et al.
Konstantinos Sapalidis et al.
Lung cancer is still diagnosed at a late stage due to lack of early disease symptoms. Despite the development of new diagnostic endoscopic tools, such as radial/convex endobronchial ultrasounds (EBUS) and electromagnetic navigation, most pa...